AR 101

Drug Profile

AR 101

Alternative Names: Characterised Peanut Allergen (CPNA) oral immunotherapy (OIT) - Aimmune Therapeutics; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Allergen Research Corporation
  • Developer Aimmune Therapeutics
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Peanut hypersensitivity
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 03 Mar 2017 Additional efficacy data from the phase I/II DEVIL trial in Peanut hypersensitivity presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 16 Feb 2017 Aimmune Therapeutics plans to initiate the phase III RAMSES trial for Peanut hypersensitivity (In adolescents, In children) in USA
  • 01 Dec 2016 Aimmune Therapeutics initiates enrolment in the ARC 004 (PALISADE follow-on) trial for Peanut hypersensitivity (In children, In adolescents, In adults) in USA (PO,capsule) (NCT02993107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top